Table 2.
Spondyloarthritis features, pharmacological treatment, and PROMs in AS, PsA or other-SpA, with IBP
| AS with current IBPa N = 319 | PsA with current IBPa N = 409 | p-value* | Other-SpA with current IBPa N = 282 | p-value** | p-value*** | |
|---|---|---|---|---|---|---|
| Demographic | ||||||
| Age 2009, mean (sd)b | 54 (13) | 57 (13) | 53 (15) | |||
| Sex, N men (%)b | 182 (57) | 129 (32) | <0.001 | 87 (31) | <0.001 | 0.860 |
| SpA-related disease, N (%) | ||||||
| Uveitisb | 63 (20) | 9 (2) | <0.001 | 37 (13) | <0.001 | <0.001 |
| Psoriasisb | 19 (6) | 407 (100) | <0.001 | 0 | ||
| Inflammatory bowel diseaseb | 25 (8) | 21 (5) | 0.901 | 36 (13) | 0.706 | 0.001 |
| PROMS, mean (95 % Cl) | ||||||
| NRS-spinal painc | 5.9 (5.6−6.1) | 6.1 (5.9−6.4) | 0.068 | 6.2 (6.0−6.5) | 0.037 | 0.688 |
| NRS-fatiguec | 5.8 (5.6−6.1) | 6.2 (5.9−6.4) | 0.044 | 6.1 (5.8−6.4) | 0.117 | 0.547 |
| NRS-patients globalc,d | 5.2 (4.9−5.4) | 5.4 (5.2−5.6) | 0.188 | 5.5 (5.2−5.7) | 0.087 | 0.850 |
| BASDAIc | 5.1 (4.8−5.3) | 5.7 (5.5−5.8) | <0.001 | 5.5 (5.3−5.8) | 0.006 | 0.530 |
| BASFIc | 4.4 (4.2−4.7) | 4.8 (4.5−5.0) | 0.093 | 4.4 (4.1−4.7) | 0.973 | 0.093 |
| EQ-5Dc | 0.68 (0.66−0.70) | 0.65 (0.63−0.67) | 0.062 | 0.67 (0.64−0.69) | 0.362 | 0.421 |
| Treatment, n (%) | ||||||
| Etanerceptb | 27 (9) | 54 (13) | 0.044 | 15 (5) | 0.150 | 0.001 |
| Adalimumabb | 12 (4) | 32 (8) | 0.027 | 9 (3) | 0.825 | 0.013 |
| Methotrexateb | 37 (12) | 151 (37) | <0.001 | 33 (12) | 1.000 | <0.001 |
| Sulphasalazineb | 28 (9) | 14 (3) | 0.003 | 24 (9) | 1.000 | 0.006 |
Abbreviations: AS ankylosing spondylitis, IBD inflammatory bowel disease, NRS numerical rating scale 1–10, BASDAI bath ankylosing spondylitis activity index, BASFI bath ankylosing spondylitis functional index, PROMs patient-reported outcome measures, IBP inflammatory back pain
Based on 2785 spondyloarthritis patients in the Skåne Health Care Register who responded to a questionnaire, registered data for 6 responders were incomplete and was thus excluded
*, **AS with current IBP vs. PsA and other-SpA with current IBP, respectively
***PsA with current IBP vs. other-SpA with current IBP
aCurrent IBP: ≥3 months of back pain in the preceding year and fulfilling the Berlin criteria for inflammatory back pain (IBP)
bData from the register (SpA-related disease 1998–2009; treatment 2005–2009)
cData from the survey
dPatient’s global assessment of back disease